In June 2009, MSD and Drugs for Neglected Diseases initiative (DNDi) entered into a master agreement to support discovery and development of improved treatments for a wide range of NTDs. The agreement covers a wide range of NTDs including visceral leishmaniasis and Chagas disease that infect millions of people. As with many other NTDs, adequate treatments suitable for poor populations are lacking. Current therapies may be toxic, prohibitively expensive, or difficult to administer, particularly in resource-poor settings. Under the terms of the agreement, MSD contributes small molecule assets and related intellectual property via a non-exclusive, royalty-free license to DNDi to conduct early development programs for drug candidates for treatment of NTDs, with the primary goal of manufacture and distribution of drugs at low cost to the public sector in resource-poor countries. MSD and DNDi share joint intellectual property on drug candidates generated through early development, and MSD retains the option to undertake late clinical development and registration of these drug candidates.